Consumer Advisor

Mitochondrial dysfunction is at the root of most all chronic diseases, and it also plays a crucial role in conditions such as long COVID, which is becoming quite common. It’s also a root factor that must be addressed in COVID jab injuries, regardless of symptoms or severity. Features of the post-jab injuries we see point to severe mitochondrial dysfunction, which in turn causes energy failure. The same goes for long COVID in people who struggle with unrelenting fatigue and other symptoms for months after they’ve recovered from COVID-19 infection.   If you can improve your mitochondrial function and restore energy supply to your cells, you’re going to massively increase your odds of reversing the problems caused by the jab or the virus.  US Life Expectancy Falls in Historic Decline Allopathic medicine has been a leading cause of death in the U.S. for over two decades. In 1998, researchers concluded that properly prescribed and correctly taken pharmaceutical drugs were the fourt

The sophisticated American consumer has grown accustomed to the gold-standard for drug and health products—the prospective Randomized, double-blind, placebo-Controlled Trial (RCT). Operation Warp Speed (OWS) was supposed to be a churning mill of large RCT’s to help the nation understand what conclusively is effective in the prevention and treatment of COVID-19. Unfortunately, after three years, has delivered failed products (remdesivir, baricitinib, molnupiravir, COVID-19 vaccines) and small inconclusive trials of products that doctors have found effective in practice including off-target generic antivirals and anticoagulants. OWS did not test simple, affordable, available prevention strategies. Fortunately such RCTs where done outside of the US and have brought us important findings. Balmforth et al, conducted a prospective double-blind, placebo-controlled trial of a xylitol based nasal spray in the prevention of SARS-CoV-2 infection in exposed healthcare workers in two hospitals in U

New study of consumers in 24 countries shows the pandemic is prompting billions ( 1 ) to consider more sustainable behaviors A large proportion of adults (85%) state they’re willing to take personal action to combat environmental and sustainability issues in 2021 New Mastercard feature enables banks to equip people with carbon footprint data and insights to help inform consumer spending and offer ways to contribute to reforestation Research on sustainability, commissioned by Mastercard, reveals a marked increase in consumer passion for the environment as a result of COVID-19. More than half of those surveyed across the world (54%) see reducing their carbon footprint as more important now than pre-pandemic. This signals a growing trend toward eco-conscious spending and consumption among people who want to turn their purchases and rewards redemption into meaningful action for the planet. To address this, Mastercard, in collaboration with Swedish fintech Doconomy, developed the  Mastercar

As the world shifts towards more environmentally friendly modes of transportation, the debate between electric and hydrogen vehicles has risen. What distinguishes these two technologies? What advantages do they offer? And which will ultimately dominate the future? How do electric and hydrogen cars work? In a comparison of electric cars vs. hydrogen cars, it is essential to first understand how each technology works. In an electric car, instead of fuel combusting to provide energy to an engine, a lithium-ion battery is used to supply electricity to a motor, which then turns the wheels and powers other elements of the car. When depleted, instead of going to a gas station, an electric car is recharged by plugging into the electricity grid, much like with a telephone or computer. A hydrogen car works differently, although it does also contain an electric motor. Inside a hydrogen-powered car, a fuel cell filled with hydrogen reacts with oxy

Executive Summary After securing US orphan designation for an artificial intelligence-assisted therapeutic, Insilico's co-CEO Feng Ren sits down for a wide-ranging interview in which he discusses why AI drug discovery is more predictable, efficient and cost-effective than the conventional bench-to-bed model. AI's limitations and validations, why the industry should get excited about algorithms, data sets and deep learning are other topics to consider in this fast-growing field.  Hong Kong- and Shanghai-based artificial intelligence drug discovery company Insilico Medicine recently had the best month in its history, as a small molecule discovered using its technology, INS018-055 for idiothetic pulmonary fibrosis (IPF), obtained orphan drug designation from the US Food and Drug Administration.  Insilico co-CEO Feng Ren comes from a chemistry background. After graduating from Harvard University in the US, he worked for GSK plc for 11 years, including a